Trial reportThe pharmacogenomics journal2012
Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes.
Trial report in The pharmacogenomics journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression.International journal of environmental research and public health · 2023Pooled it
- Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial.Addiction (Abingdon, England) · 2025Trial
- Impact of early nausea on varenicline adherence and smoking cessation.Addiction (Abingdon, England) · 2020Trial
- Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013Trial
- Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.Pharmacogenetics and genomics · 2013Trial
- The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial.Clinical pharmacology and therapeutics · 2012Trial
- Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review.BMC public health · 2024Review
- CHRNA5 links chandelier cells to severity of amyloid pathology in aging and Alzheimer's disease.Translational psychiatry · 2024Article
- A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations.Frontiers in genetics · 2023Article
- Population pharmacokinetics and exposure-response analyses of varenicline in adolescent smokers.CPT: pharmacometrics & systems pharmacology · 2021Article
- Article
- Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018Review
- Significant association of the CHRNB3-CHRNA6 gene cluster with nicotine dependence in the Chinese Han population.Scientific reports · 2017Article
- α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.Movement disorders : official journal of the Movement Disorder Society · 2015Article
- Article
- CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy.Frontiers in genetics · 2015Article
- Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.The Journal of pharmacology and experimental therapeutics · 2013Article
- The Twin Research Registry at SRI International.Twin research and human genetics : the official journal of the International Society for Twin Studies · 2013Article
- The genetics of addiction-a translational perspective.Translational psychiatry · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 1 country.
Funding
Abstract
This study evaluated association between common and rare sequence variants in 10 nicotinic acetylcholine receptor subunit genes and the severity of nausea 21 days after initiating the standard, Food and Drug Administration-approved varenicline regimen for smoking cessation. A total of 397 participants from a randomized clinical effectiveness trial with complete clinical and DNA resequencing data were included in the analysis (mean age=49.2 years; 68.0% female). Evidence for significant association between common sequence variants in CHRNB2 and nausea severity was obtained after adjusting for age, gender and correlated tests (all P(ACT)<0.05). Individuals with the minor allele of CHRNB2 variants experienced less nausea than did those without the minor allele, consistent with previously reported findings for CHRNB2 and the occurrence of nausea and dizziness as a consequence of first smoking attempt in adolescents, and with the known neurophysiology of nausea. As nausea is the most common reason for discontinuance of varenicline, further pharmacogenetic investigations are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.